This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva fine sees EU break new antitrust ground on patents, disparagement

By Lewis Crofts ( October 31, 2024, 17:08 GMT | Comment) -- Teva Pharmaceuticals today bore the brunt of the EU's latest antitrust clampdown in the pharma sector, seeing sanctions for two new breeds of conduct: patent game-playing and trash-talking rivals. While the company will certainly contest the novel theories in court, the commission will stress it isn't questioning the entire system of “divisional” patents — just abusive conduct that stops that system working.Corporate boardrooms will take note of today’s eye-watering fine of 462.6 million euros ($500 million) imposed on Teva for abusing the market for a multiple sclerosis treatment, but it is the legal innovations of the decision that may have the longer-lasting impact....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections